Amazon is poised to win in health care, says AllTrails co-founder Jeremy Cotter
Jeremy Cotter, AllTrails co-founder and early Facebook employee, joins 'Closing Bell' to discuss YouRise Health, AI's impact on health care and much more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Transgene completes initial screening in Phase II part of TG4050 vaccine trial
Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of individualised neoantigen therapeutic vaccine, TG4050, as a monotherapy in the adjuvant treatment of human papillomavirus (HPV)-negative squamous head and neck cancers. The vaccine is based on the myvac platform powered by its partner NEC's AI to enhance antigen selection. During the Phase I portion of the trial, all subjects treated with the vaccine remained disease-free post a minimum follow-up of two years, demonstrating clinical proof of principle. Translational data indicated that these subjects showed sustained T cell responses at 24 months. Meeting all trial endpoints, the findings were shared at the American Society of Clinical Oncology (ASCO 2025) annual meeting. The company anticipates completing the randomisation of all subjects in the Phase II part by the end of this year, after a second screening carried out post-surgery and adjuvant radiotherapy. Around 80 subjects who have completely responded to adjuvant therapy are expected to be enrolled and randomised in the Phase I/II trial. The first immunogenicity data from the Phase II part are projected to be available in the second half of 2026, with preliminary efficacy data anticipated in the second half of 2027. The trial is assessing the treatment benefits of the vaccine in individuals at risk of relapse. So far, 32 evaluable patients have been included in the Phase I part, with the Phase II continuing globally. Transgene chief medical officer Dr Emmanuelle Dochy said: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. 'With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and, at the same time, explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' "Transgene completes initial screening in Phase II part of TG4050 vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Forbes
an hour ago
- Forbes
The Low-Hanging Fruit That Can Transform Healthcare Today
Kamal Anand, chief product officer of TeleVox and Mosaicx, part of West Technology Group. In conversations across the healthcare industry, I see many healthcare leaders rightly focused on AI's long-term potential. But in doing so, they may overlook high-impact automation and digital engagement tools that can improve efficiency, reduce administrative burden and enhance patient experience and outcomes right now. I believe in the power of automation and AI as augmentation tools. The most effective technologies currently in healthcare aren't designed to take over for humans; they're built to support them. They help care teams focus on what they do best while offloading the repetitive, routine and administrative work that weighs them down. As a pragmatic product leader, I've seen firsthand that incremental improvements, particularly those powered by responsible AI and automation, can drive real, measurable impact. These smaller wins build confidence, prove ROI and pave the way for more transformative change down the road. By reframing digital transformation as a process of enhancement rather than disruption, healthcare leaders can unlock value sooner and with less risk. And they don't need to wait for external technology partners or major capital investment to do it. The opportunity lies in optimizing underused capabilities and aligning existing systems around immediate pain points. Transformation doesn't always mean disruption; it often means prioritization. While disruption focuses on replacing existing processes, true transformation enhances what already works. Many healthcare organizations are stalled by complexity, under-resourced teams or the misconception that meaningful change requires a wholesale overhaul. The result is digital paralysis—a wait-and-see posture that slows progress and sidelines practical improvements. Leaders often feel pressured to make one big bet on AI or commit to large-scale electronic health record (EHR) upgrades, rather than sequencing more minor improvements that can demonstrate value quickly. However, incremental progress compounds. One study suggests that even a targeted workflow fix—automating a common task or reducing administrative rework—can deliver immediate returns and help teams build the momentum and trust needed to take on more ambitious projects. There's also a misperception that if a solution isn't revolutionary, it's not worth the investment. But in healthcare, efficiency and access are deeply intertwined. In many cases, existing platforms already contain the capabilities needed to drive meaningful change, provided they're activated and aligned effectively. Here are three areas healthcare organizations can win by adopting a "start small, scale smart" strategy, without tearing down and replacing existing systems. Giving patients the ability to manage their care experience—like scheduling, prescription refills or updating forms—can ease administrative burdens and improve satisfaction. However, many health systems still require patients to use a single channel, such as a web portal, which limits adoption. A better approach is to meet patients where they are by offering self-service across channels they already use, including voice, text and online. Starting small means identifying one high-volume task and then piloting automation with clear feedback loops. Use existing tools where possible and ensure staff workflows evolve alongside tech so that value isn't lost to confusion or duplication. Referrals to specialists often involve manual outreach, missed calls and follow-up delays. For large systems, only a minority of referrals, as low as 34.8%, turn into appointments. That's lost revenue—and worse, delayed care. One way to begin automating this flow is by building logic into your existing customer relationship management (CRM) system that triggers outreach once a referral is made. Let patients schedule through secure text, voice or online systems, and use reminders to reduce no-shows. Even partial automation can reduce leakage and free up scheduling staff. The key is to avoid changing everything at once. Focus on one specialty or location and scale from there. Conversational AI tools have evolved far beyond basic chatbots. Today's AI-powered messaging systems can do more than help answer questions—they can provide educational resources and help patients navigate their care journeys. These systems scale communication efforts while preserving the human touch. For example, a conversational AI system might guide a patient through pre-visit instructions, post-discharge care or insurance questions, only escalating to a live agent when needed. The study mentioned above indicates that AI-powered chatbots help reduce healthcare providers' workloads, allowing them to concentrate on more complicated cases that require their expertise. These tools minimize call center strain, improve response times and keep patients engaged throughout the care continuum by handling routine inquiries and providing around-the-clock support. Organizations don't need to build from scratch to get started. Many can pilot AI-powered messaging by extending their current patient communication platforms or integrating with existing CRM systems. A small-scale rollout, such as AI for pre-visit preparation or post-discharge follow-up, can help teams test effectiveness, gather feedback and gradually expand based on need and performance. Generative and agentic AI may be stealing the spotlight, but it's not the only form of intelligent technology delivering value in healthcare today. Leaders don't need to start with the most advanced capabilities to move the needle. Beginning with smaller, manageable steps sets the stage for faster adoption, clearer ROI and more substantial team alignment. Getting started doesn't require major system upgrades. Many teams already have the infrastructure they need to begin automating routine workflows, whether it's appointment reminders, referral scheduling or billing notifications. The key is to take a realistic inventory of current platforms, identify friction points and apply automation where it can quickly relieve pressure. Internal alignment matters just as much as the tech stack. Teams should be looped in early, with clear expectations around what automation will do and how it fits into their day-to-day responsibilities. Focus on projects that improve staff workflows, not just patient-facing touchpoints. Small efficiency wins—like reducing phone traffic or eliminating redundant data entry—can deliver measurable time savings and morale boosts. Ultimately, digital transformation doesn't have to feel disruptive. With the proper framing, small-scale automation projects become a proving ground for larger innovation. They help teams build confidence, develop governance practices and scale what works. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Yahoo
an hour ago
- Yahoo
Cheetah Mobile First Quarter 2025 Earnings: CN¥1.10 loss per share (vs CN¥2.68 loss in 1Q 2024)
Revenue: CN¥259.0m (up 36% from 1Q 2024). Net loss: CN¥33.4m (loss narrowed by 58% from 1Q 2024). CN¥1.10 loss per share (improved from CN¥2.68 loss in 1Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Software industry in the US. Performance of the American Software industry. The company's shares are up 2.0% from a week ago. Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Cheetah Mobile's balance sheet health. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
